Navigation Links
Feola, at University of Kentucky, receives NIH grant to study cystic fibrosis
Date:5/24/2012

LEXINGTON, Ky. (May 24, 2012) David Feola, a University of Kentucky College of Pharmacy faculty member in the Department of Pharmacy Practice and Science, received a five-year, $1.8 million grant from the National Institutes of Health (NIH) to continue his research investigating immune responses in the lungs that will potentially lead to the discovery of medical treatments for patients with cystic fibrosis and other chronic pulmonary inflammatory conditions.

Cystic fibrosis is a life-threatening disease that causes mucus in the lungs to become too thick, which leads to severe pulmonary complications. This disease is one of the most common chronic lung diseases in children and young adults, affecting 30,000 children and adults in the United States and nearly 70,000 people worldwide, according to the Cystic Fibrosis Foundation.

Feola's research lab focuses on the regulatory function of macrophages, an immune cell type that kills invading pathogens and controls inflammation, in patients with chronic pulmonary inflammatory diseases. Cystic fibrosis causes progressive, life-threatening lung damage due in large part to repeated, dysregulated inflammatory responses to bacterial infection. Preliminary research in Feola's lab suggests that inducing specific types of macrophage activation could blunt this dysregulated inflammation. This research will lead to discovery of specific drug targets that could slow or halt this destructive cycle of inflammatory injury and pulmonary function decline in these patients.

"It is our hope that this research funding will provide us a greater understanding on how cystic fibrosis works, discover novel ways of treating the disease, and how we might be able to improve quality of life for these patients," said Feola, who also is a two-time graduate of the UK College of Pharmacy. Feola received his PharmD and PhD from the College.

Feola's grant is an investigator-initiated Research Project (R01) award, which is being funded by NIH's National Institute of Allergy and Infectious Diseases. R01 grant funding has become increasingly competitive due to the nation's current economic condition.

"The funding of this NIH grant is a testament to Dr. Feola's skill, expertise, tenacity and perseverance in pursing this support for his research program," said Linda Dwoskin, Associate Dean for Research for the UK College of Pharmacy. "I am extremely happy for him, his lab and the Pharmacy Practice and Science Department. I look forward to hearing about the great discoveries that result from Dr. Feola's research on cystic fibrosis."


'/>"/>

Contact: Allison Elliott
allison.elliott@uky.edu
University of Kentucky
Source:Eurekalert

Related medicine news :

1. McMaster University researchers discover drug destroys human cancer stem cells but not healthy ones
2. University studies and career expectations of medical students
3. University of Minnesota startup to treat challenging bacterial infection
4. Columbia University Medical Center and NY-Presbyterian experts at APA meeting
5. University of Houston Graduate College of Social Work announces partnership with MD Anderson
6. Neuropsychologist receives University of Houstons highest faculty honor
7. Louisiana Tech University professor earns NSF Early Career Development grant
8. Rice University student engineers automate limb lengthening for kids
9. Leading experts on congenital muscular dystrophy convene at University of Nevada, Reno
10. University of Cincinnati researchers win $3.7M grant from US Department of Defense
11. Oxford University Press partners with the Physical Society of Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... “End Time GPS”: ... events will interrelate. “End Time GPS” is the creation of published author, Wesley ... while working on military munitions and space-vehicle projects. Now, at age ninety-one, he shares ...
(Date:3/23/2017)... Seattle, WA (PRWEB) , ... March 23, 2017 , ... ... emergency and now estimates that there could be four million Zika-related cases in the ... to date with numbers of US cases reported per year skyrocketing to an estimated ...
(Date:3/23/2017)... Braunfels, TX (PRWEB) , ... March 23, 2017 , ... ... new clinic, located at 960 Gruene Road in Building 2. The clinic is the ... Dr. Andrew Bennett, PT, says opening the company’s second New Braunfels location brings things ...
(Date:3/23/2017)... ... ... are unaware of the dangers that infectious bacteria play in mouth disease, while 1 out ... that dentists recommend. The ramifications of improper oral upkeep go far beyond bad breath and ... hours of work each year due to dental issues. That is why Mediaplanet is proud ...
(Date:3/23/2017)... ... March 23, 2017 , ... The StayWell Company announced today ... accreditation covers StayWell’s asthma, coronary artery disease, congestive heart failure, chronic obstructive pulmonary ... have excellent programs for the delivery and improvement of disease management and that ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... Research and Markets has announced the addition of the ... ... oxygen therapy devices market to grow at a CAGR of 10.16% ... Therapy Devices Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
(Date:3/23/2017)... A research report by Mordor Intelligence ... reach USD 7.2 billion by the end of 2021 and ... procedure in which a sample is preserved prior to its ... since the methods are often allowing repeated testing. The report ... shared procedures in the lab. In many life science labs, ...
(Date:3/23/2017)... BOSTON , March 23, 2017 ... respond optimally to most vaccines because their young ... researchers at Boston Children,s Hospital report achieving strong ... the final preclinical model before human trials — ... the immune response. In two simultaneous papers, they ...
Breaking Medicine Technology: